News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
281,646 Results
Type
Article (14896)
Company Profile (299)
Press Release (266445)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79865)
Career Advice (162)
Deals (13336)
Drug Delivery (39)
Drug Development (50698)
Employer Resources (31)
FDA (5837)
Job Trends (5167)
News (145106)
Policy (10072)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (920)
Accelerated approval (19)
Adcomms (14)
Allergies (81)
Alliances (21768)
ALS (125)
Alzheimer's disease (1031)
Antibody-drug conjugate (ADC) (241)
Approvals (6032)
Artificial intelligence (259)
Autoimmune disease (111)
Automation (9)
Bankruptcy (105)
Best Places to Work (4560)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (45)
Breast cancer (344)
Cancer (3130)
Cardiovascular disease (237)
Career advice (147)
Career pathing (7)
CAR-T (217)
CDC (5)
Cell therapy (563)
Cervical cancer (14)
Clinical research (43669)
Collaboration (1148)
Company closure (2)
Compensation (596)
Complete response letters (39)
COVID-19 (1100)
CRISPR (86)
C-suite (550)
Cystic fibrosis (112)
Data (4321)
Denatured (15)
Depression (92)
Diabetes (254)
Diagnostics (1379)
Digital health (10)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (188)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (215)
Earnings (31659)
Editorial (25)
Employer branding (4)
Employer resources (29)
Events (51662)
Executive appointments (621)
FDA (7588)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (981)
Gene editing (182)
Generative AI (21)
Gene therapy (487)
GLP-1 (504)
Government (1147)
Grass and pollen (3)
Guidances (166)
Healthcare (6611)
HIV (18)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (190)
Immuno-oncology (39)
Indications (66)
Infectious disease (1204)
Inflammatory bowel disease (156)
Inflation Reduction Act (10)
Influenza (38)
Intellectual property (166)
Interviews (18)
IPO (7345)
IRA (12)
Job creations (867)
Job search strategy (129)
JPM (40)
Kidney cancer (9)
Labor market (22)
Layoffs (243)
Leadership (9)
Legal (1401)
Liver cancer (41)
Longevity (11)
Lung cancer (420)
Lymphoma (249)
Machine learning (24)
Management (7)
Manufacturing (376)
MASH (130)
Medical device (2662)
Medtech (2671)
Mergers & acquisitions (6614)
Metabolic disorders (724)
Multiple sclerosis (104)
NASH (13)
Neurodegenerative disease (230)
Neuropsychiatric disorders (70)
Neuroscience (1953)
Neurotech (1)
NextGen: Class of 2026 (2034)
Non-profit (866)
Now hiring (30)
Obesity (329)
Opinion (125)
Ovarian cancer (131)
Pain (102)
Pancreatic cancer (161)
Parkinson's disease (232)
Partnered (12)
Patents (301)
Patient recruitment (329)
Peanut (43)
People (26657)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15475)
Phase 2 (20289)
Phase 3 (12820)
Pipeline (3252)
Policy (90)
Postmarket research (853)
Preclinical (6535)
Press Release (30)
Prostate cancer (145)
Psychedelics (50)
Radiopharmaceuticals (238)
Rare diseases (648)
Real estate (1450)
Recruiting (12)
Regulatory (9896)
Reports (19)
Research institute (971)
Resumes & cover letters (18)
Rett syndrome (24)
RNA editing (21)
RSV (16)
Schizophrenia (123)
Series A (182)
Series B (136)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2005)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (333)
Venture capital (69)
Weight loss (173)
Women's health (25)
Worklife (2)
Date
Today (25)
Last 7 days (340)
Last 30 days (1140)
Last 365 days (17822)
2026 (1677)
2025 (18098)
2024 (20543)
2023 (22414)
2022 (26822)
2021 (27807)
2020 (23359)
2019 (16224)
2018 (11739)
2017 (13745)
2016 (11840)
2015 (14352)
2014 (10395)
2013 (7486)
2012 (7533)
2011 (7617)
2010 (7430)
Location
Africa (154)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18254)
Australia (3111)
California (7077)
Canada (1837)
China (773)
Colorado (246)
Connecticut (252)
Delaware (235)
Europe (39162)
Florida (903)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (395)
India (35)
Indiana (160)
Iowa (8)
Japan (222)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (736)
Massachusetts (5585)
Michigan (110)
Minnesota (248)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (32)
New Hampshire (21)
New Jersey (1646)
New Mexico (13)
New York (1762)
North Carolina (827)
North Dakota (6)
Northern California (3475)
Ohio (177)
Oklahoma (11)
Oregon (24)
Pennsylvania (1276)
Puerto Rico (9)
Rhode Island (25)
South America (215)
South Carolina (9)
Southern California (2808)
Tennessee (40)
Texas (906)
United States (23338)
Utah (96)
Virginia (136)
Washington D.C. (37)
Washington State (592)
West Virginia (1)
Wisconsin (45)
281,646 Results for "apogee therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026
February 5, 2026
·
1 min read
Press Releases
Apogee Therapeutics to Participate in Upcoming Conferences
November 4, 2025
·
1 min read
Press Releases
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering
October 9, 2025
·
5 min read
Press Releases
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results
November 10, 2025
·
12 min read
Press Releases
Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering
October 9, 2025
·
5 min read
Press Releases
Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum
September 3, 2025
·
1 min read
Press Releases
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026
January 6, 2026
·
1 min read
Press Releases
Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody
November 10, 2025
·
6 min read
Press Releases
Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook
January 6, 2026
·
10 min read
Press Releases
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results
August 12, 2025
·
13 min read
1 of 28,165
Next
